Successful Revascularization of Acute Carotid Stent Thrombosis by Facilitated Thrombolysis

References

1. ↵
   Moussa I, Gishel N, Lawrence E, et al. Clopidogrel may enhance the clinical efficacy of carotid artery stent implantation: the EMILY registry. Stroke 2000;31:299
2. ↵
   Wholey MH, Wholey M. Current status in cervical carotid artery stent placement. J Cardiovasc Surg 2003;44:331–339

   PubMed
3. ↵
   Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 2002;87:1020–1025

   PubMedWeb of Science
4. ↵
   Luciardi H, Berman S, Muntaner J, et al. Facilitated thrombolysis: dethrombosis? Clin Appl Thromb Hemost 2002;8:133–138

   Abstract/FREE Full Text
5. ↵
   North American Symptomatic Carotid Endarterectomy Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–453

   CrossRefPubMedWeb of Science
6. ↵
   Tong FC, Cloft HJ, Joseph JJ, et al. Abciximab rescue in acute carotid stent thrombosis. AJNR Am J Neuroradiol 2000;21:1750–1752

   Abstract/FREE Full Text
7. ↵
   Chaturvedi S, Sohrab S, Tselis A. Carotid stent thrombosis: report of 2 fatal cases. Stroke 2001;32:2700–2702

   Abstract/FREE Full Text
8. ↵
   Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371–380

   PubMed
9. ↵
   Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551–1556

   Abstract/FREE Full Text
10. ↵
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587

    CrossRefPubMedWeb of Science
11. ↵
    Hahnel S, Schellinger PD, Gutschalk A, et al. Local intra-arterial fibrinolysis of thromboemboli occurring during neuroendovascular procedures with recombinant tissue plasminogen activator. Stroke 2003;34:1723–1728
12. ↵
    Kapadia SR, Bajzer CT, Ziada KM, et al. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 2001;32:2328–2332

    Abstract/FREE Full Text
13. ↵
    Kopp CW, Steiner S, Nasel C, et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke 2003;34:2560–2567

    Abstract/FREE Full Text
14. ↵
    The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601–609

    Abstract/FREE Full Text
15. ↵
    Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial: the TIMI 14 Investigators. Circulation 1999;99:2720–2732

    Abstract/FREE Full Text
16. ↵
    Eckert B, Koch C, Thomalla G, et al. Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke 2002;33:1424–1427

    Abstract/FREE Full Text
17. ↵
    Joung P, Cohen EA, Batchelor W, et al. Bleeding risk with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001;141:218–225

    CrossRefPubMedWeb of Science
18. ↵
    Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003;107:1840–1843

    Abstract/FREE Full Text
19. ↵
    Qureshi AI, Siddiqui AM, Suri MFK, et al. Aggressive mechanical clot disruption and low dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002;51:1319–1329

    PubMedWeb of Science
20. ↵
    Hoffmeister HM, Szabo S, Kastner C, et al. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin. Circulation 1998;98:2527–2533

    Abstract/FREE Full Text
21. ↵
    Klein B, Faridi A, von Temelhoff GF, et al. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 2003;108:291–296
22. ↵
    Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002–1006

    CrossRefPubMedWeb of Science
23. ↵
    Steiner S, Seidinger O, Huber K, et al. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003;23:1697–1702.

    Abstract/FREE Full Text